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A total of 120 Burkholderia cepacia complex isolates collected during 2004 –2010 from 66 patients in two cystic fibrosis reference
centers in Argentina were analyzed. Burkholderia contaminans was the species most frequently recovered (57.6%), followed by
Burkholderia cenocepacia (15%), a species distribution not reported so far. The recA-PCR-based techniques applied to the B.
contaminans isolates revealed that 85% of the population carried the recA-ST-71 allele. Our results showed the utility of BOX-
PCR genotyping in analyzing B. contaminans diversity. This approach allowed us to address clonal transmission during an out-
break and the genetic changes occurring in infecting bacteria over the course of chronic infection.
Burkholderia cepacia complex species are capable of causingchronic and often severe respiratory tract infections in cystic
fibrosis (CF) patients and other types of infections in immuno-
compromised patients. Although many CF patients remain in-
fected by these bacteria and yet stay relatively healthy for pro-
longed periods, others either have a severe decline in their
pulmonary status or die shortly after the initial colonization (1).
In Argentina, the first reports of B. cepacia complex bacteria in-
fecting CF patients started around 1990. At that time, Burkhold-
eria spp. were recovered sporadically and with a very low preva-
lence (,0.1%). The prevalence increased over the last decade
from 0.2 to 3.6%, depending on the medical center. In early 2004,
an outbreak involving main Argentine CF care centers occurred,
and the proportion of patients from whom B. cepacia complex
species were recovered ranged from 19 to 36% (2–4). Currently,
through strict infection control procedures, the prevalence of
Burkholderia spp. in local patients has decreased to approximately
10%. Recent worldwide surveillance studies concerning the distri-
bution of B. cepacia complex species in CF patients have cited B.
multivorans and B. cenocepacia as the most frequently recovered
species. These species account for approximately 80% of the in-
fected patients, and the prevalence of one or the other is geograph-
ically and temporally dependent (5–7). Unlike this worldwide sit-
uation, in Argentina a relatively high prevalence ofB. contaminans
followed byB. cenocepacia has been observed (3, 4). To our knowl-
edge, no other geographical region has been reported in the liter-
ature to have such a high occurrence of B. contaminans infecting
CF patients. In view of this particular scenario, coupled with the
lack of biodiversity information available for B. contaminans spe-
cies, we decided to study this local population by recA-PCR-based
techniques and by repetitive element sequence-based PCR (rep-
PCR) approaches. These methods allowed us to address the ge-
netic diversity of B. contaminans isolates recovered during that
outbreak along with the genetic changes occurring in the infecting
bacteria over the course of a chronic infection.
Distribution of Burkholderia cepacia complex species in CF
patients. This study involved the analysis of a total of 120 clinical
Burkholderia cepacia complex isolates recovered from 66 CF pa-
tients from 2004 through 2010 and 13 reference strains (see Table
S1 in the supplemental material). The isolates were recovered from
sputum samples of CF patients treated at two main CF reference
centers ofArgentina (Hospital deNiños SorMaríaLudovica, LaPlata
[HNLP], and Hospital Santísima Trinidad, Córdoba [HST], located
800 km north of La Plata) plus one hospital (Hospital Dr. Pedro
Moguillanski, Cipoletti, Río Negro [HNRN], 1,200 km south of La
Plata). Twenty-two isolates (indicated with a “v” in Table S1 in the
supplemental material) were withdrawn from patients infected dur-
ing the B. cepacia complex outbreak, and a cohort of 51 isolates was
recovered from 21 patients chronically infected with B. cepacia com-
plex bacteria. Patients were considered chronically infected when
three positive cultures of B. cepacia complex strains were isolated
within a 6-month period (8). Bacterial isolationwas performed onB.
cepacia selective agarmedium(BCSA; LaboratoriosBritania S.A., Ar-
gentina) according to clinical microbiology practice recommenda-
tions for respiratory tract specimens fromCFpatients (9, 10), and the
strains recoveredwerephenotypically characterizedbymeansof con-
ventional biochemical techniques (9–12). The species-level identifi-
cation was achieved by recA-PCR-based techniques. The recA gene
(1,040 bp)was amplifiedwithBCR1 andBCR2primers (13), and the
amplified products were subjected to restriction fragment length
polymorphism (RFLP) analysis with the restriction enzyme HaeIII
(Promega, Inc.) (13). The restriction PCR patterns obtained were
analyzed and comparedwith those reported in the literature (13–16).
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The amplified products were purified with a QIAquick PCR purifi-
cation kit (Qiagen Inc., CA) and sequenced on both strands with the
BigDye terminator cycle sequencing ready reaction kit (Applied Bio-
systems, Foster City, CA) at Macrogen, Inc. (Seoul, South Korea). A
final identification was achieved by recADNA sequence analysis and
by gyrBDNA fragment (1,900 bp) sequencingwhen an identification
remained ambiguous. The recA sequence type (recA-ST) within each
species was obtained by comparing the sequence of a 393-bp recA
fragment against the multilocus sequence typing (MLST) database
(http://pubmlst.org/bcc/) (1).
The analysis of species distribution among the patients studied
showed that 8 of the 17 species described for the B. cepacia com-
plex had infected the local CF population, with a remarkably high
representation of B. contaminans, i.e., 57.6% of the infected pa-
tients. The data on the species of the first isolate available from
each patient indicated that B. cenocepacia was the second most
frequent species, it encountered at a frequency of almost 15% of
the patients, followed by B. cepacia at 7.5%, B. multivorans at
6.0%, B. stabilis and B. vietnamiensis at 5%, B. seminalis at 3.0%,
and B. ambifaria at 1.5%.
In order to examine the genetic diversity among the B. con-
taminans isolates, sequence analysis of a 900-bp fragment of the
recA gene was performed for the 79 B. contaminans isolates (see
Table S1 in the supplemental material). The phylogenetic rela-
tionship among themwas investigated by usingMEGAversion 4.0
software (http://www.megasoftware.net) (Fig. 1). Isolates were
clearly separated into one large homogenous cluster that grouped
85%of theB. contaminanspopulation under study together, along
with four small clusters containing only 5 isolates in total. When
the sequence of the 393-bpDNA fragment from the recA gene was
compared against theMLST database (1), all the bacteria included
in the main cluster were found to belong to the recA-ST-71 allele,
while 4 of the isolates grouping outside this cluster displayed dif-
ferent recA-ST alleles (ST-64, -166, and -243). The isolates
grouped in the main cluster had a recA-HaeIII restriction pattern
corresponding to the K type, whereas the isolates outside this
group gave profiles of K, AT, and J (see Table S1 in the supple-
mental material). Interestingly, one of the isolates (HNLP 1001)
exhibited the J recA-RFLP pattern, which was reported to be rep-
resentative of the species B. cenocepacia, B. stabilis, B. lata, B. semi-
nalis, and B. arboris (13, 17, 18) but has not been documented so
far forB. contaminans. It is notable that none of the recA sequences
corresponding to isolates that grouped in the main cluster was
represented by the recA reference sequences available at GenBank.
It should also be remarked that two reference sequences display-
ing the recA-ST-71 allele, those belonging to two isolates recov-
ered from CF patients in Brazil (B. contaminans R18428 and
R9929), clustered at a short distance from the homogenous cluster
(Fig. 1). A further exploration of a possible regional incidence ofB.
contaminans among isolates circulating in Brazil should prove in-
teresting. In this regard, the incidence of RFLPK pattern strains in
CF patients seen at two different hospitals in Brazil (15, 19) might
also indicate the existence of regional spreading of B. contaminans
between bordering countries.
Genetic diversity among B. contaminans isolates with the
recA-ST-71 allele as investigated by rep-PCR DNA fingerprint-
ing analysis. The low level of polymorphism in the recA gene
encountered in the B. contaminans population studied here
prompted us to explore the genetic diversity among the isolates
carrying the recA-ST-71 allele by rep-PCR (20). This subset of 75
B. contaminans isolates was analyzed by repetitive extragenic pal-
indromic (REP), enterobacterial repetitive intergenic consensus
(ERIC), and BOX-PCRs. Amplification reactions were performed
in a MyCycler thermal cycler (Bio-Rad) with the primers
REP1R-I, REP2-I, ERIC1R-I, and BOX-A1R (20). The amplicons
generated were electrophoresed in agarose gels, and the banding
patterns obtained were analyzed with the GelCompar II version
2.1 software package (Applied Maths, Kortrijk, Belgium). The
profiles yielding a band similarity of 85%ormorewere considered
related clones for all assays. According to this criterion, both REP
and ERIC banding patterns displayed a very limited diversity.
With the REP primers, the isolates showed only four different
banding patterns, with one being observed in 92% of the isolates.
Similarly, whenERIC-PCRprimerswere used, 5 different patterns
were found, with one subtype including 89% of the isolates (data
not shown). The highest discrimination powerwas obtainedwhen
BOX-PCR was performed. This fingerprint typing yielded 10 dis-
tinct amplification profiles (B1 to B10) (Fig. 2). The distribution
of the isolates’ amplification profiles was as follows: subtype B8,
50%; subtype B1, 22.9%; subtypes B6 and B7, 6.75%; subtype B9,
5.4%; and subtypes B2, B3, B7, B5, and B10, 1.35% (these com-
prised only 1 isolate each).
The first B. contaminans isolate recovered from each patient
over the period 2004–2010was used to determine the incidence of
each BOX subtype. Three subtypes, B1, B7, and B8, were the most
abundant patterns found, altogether accounting for 75% of the
isolates. The B6 subtype was observed in 3 patients, while the
remaining 6 subtypes were unique fingerprints observed in only
one patient each (Fig. 3A). With respect to geographical distribu-
tion, whereas the isolates with B7 and B8 subtypes were found at
both reference centers at a remarkably high incidence, all the other
BOX subtypes were present at only one of the two locations (Fig.
3B). Thus, although the interpatient transmission of B. contami-
nanswith the B7 and B8 BOX subtypes could very likely have been
a dominant occurrence at both CF centers, other sources of new
infections were clearly present. Regarding the prevalence of each
BOX subtype over time, during the period of the outbreak (2004–
2005), the CF patients were in most instances infected with the B8
(55%), B7 (15%), and B6 (11%) subtypes but were also infected,
in a much lower proportion, with isolates belonging to other ge-
notypes (B2, B3, B4, B9, and B1) (Fig. 3C).We therefore infer that
the isolates belonging to the B8 genotype (and to a lesser extent to
B7) were efficiently transmitted at the outbreak period to produce
a clonal spreading among the patients (Fig. 3B and C). Neverthe-
less, the fact that other unique BOX subtypes (e.g., the B2, B3, B4,
B9, and B10 subtypes) were also present should be stressed
(Fig. 3C). Hence, as previously reported for different Burkholderia
sp. outbreaks (21), although a high number of infections could
have been the result of particular BOX subtype patient transmis-
sion, other sources of infection—such as the environment or in-
dustrial products—might have accounted for the infections in CF
patients within that period. Additionally, it should be noted that
since 2005, isolates belonging to BOX subtypes B1 and B8 most
notably seem to be responsible for new infections in CF patients.
The PCR fingerprinting techniques have been successfully used
for B. cenocepacia, B. cepacia, B. multivorans, B. dolosa, and B.
pseudomallei clinical isolate discrimination (21, 22). In fact, ERIC-
and BOX-PCR have proven to be valid technical alternatives to
pulsed-field gel electrophoresis (22–24). In the present work, we
were able to demonstrate that BOX-PCR is also a reliable typing
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method to examine the genetic relatedness among B. contaminans
isolates so as to enable the identification of spreading of two dif-
ferent genotypes within a very closely related group of isolates.
B. contaminans diversity in chronically infected patients. CF
patients are known to be susceptible to respiratory-tract chronic
infection by certain Burkholderia species (25). Both the persis-
tence of the same strain and the colonizationwith a different strain
during the course of long-term infection have been reported (25–
FIG1 Phylogenetic tree of the 79B. contaminansCF isolates (see Table S1 in the supplementalmaterial) based on the analysis of a 900-bp recA fragment sequence
using the neighbor-joiningmethod. Bootstrap values greater than 70% are shown for 1,500 replicates. FiveB. contaminans reference sequences obtained from the
GenBank sequence database were included in the analysis (accession numbers in parentheses). recA sequence types (recA-STs) were obtained by comparing the
sequence of a 393-bp recA fragment against the public MLST database (http://pubmlst.org/bcc/). Burkholderia xenovorans was used as the outgroup.
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27). In 8 of the 21 chronically infected patients analyzed during the
7-year period of this work, more than one Burkholderia species
was recovered during the course of infection (Table 1), either as a
consequence of coinfection or through subsequent colonization
by different species (so-called “species replacement”). In contrast,
in the remaining 13 chronically infected patients, only one species
(B. contaminans) was obtained (Table 1). Upon consideration of
the BOX subtypes of serially recovered isolates during the infec-
tion of each of these 13 patients, we found that 5 patients remained
infected with isolates carrying the same BOX subtype, whereas the
other 8 evidenced a change in their isolate’s BOX subtype during
chronic infection. The latter result again could have occurred ei-
ther as a consequence of a strain replacement event or through
coinfection, with different isolates being collected—completely
by chance—at the different samplings (28). In addition, the BOX-
PCRdiversity among the isolates recovered throughout the course
of prolonged infection demonstrated that those clones isolated
FIG 2 Dendrogram showing the relatedness among representative BOX-PCR
fingerprinting patterns obtained from Burkholderia contaminans recA-ST-71
clinical isolates. The dendrogram was produced by the UPGMA (unweighted
pair groupmethod with arithmetic average) method. Clusters were delineated
with an 85%-similarity cutoff value, as indicated by the vertical line. One
isolate representative of each pattern is indicated.
FIG 3 Distribution of BOX-PCR subtypes (B1 to B10) of B. contaminans isolates with the recA-ST-71 allele obtained over a 7-year period, with only the first
isolate recovered from each patient being considered. (A) Incidence; (B) geographical distribution; (C) temporal distribution.
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during the first year or years of infection belonged to different
BOX subtypes (B6 to B8), with the B8 subtype being predomi-
nant—probably since the sample collection overlapped with the
outbreak period (2004–2005). In contrast, after a long-lasting in-
fection (more then 3 years of being colonized by B. contaminans),
either the B1 or B8 BOX subtype became predominant, and the
two were likely coexistent (28). Therefore, we conclude that the
BOX-subtype diversity of the infecting strains responsible for the
chronic cases investigated seemed to decrease over the time of
infection, with B1 and B8 subtypes being the ones that mostly
persisted and, apparently, replacing the initially infecting strains.
This type of occurrence was found to be common in P. aeruginosa
infections, where after a period of recurrent colonization, the CF
patients became colonized permanently with a single lineage (29,
30). Once this P. aeruginosa lineage became adapted to the hostile
environment of the CF lung (i.e., as the “adapted dominant epi-
demic strain”), that bacterium could persist for several decades so
as to overcome both the host defense mechanisms and any inten-
sive antibiotic therapy (29, 31–33).
In conclusion, the species B. contaminans was indeed able to
develop chronic colonization in CF patients. In particular, isolates
belonging to BOX subtypes B8 and B1 persisted during the 7 years
of our surveillance, either infecting CF patients for the first time
(Fig. 3C) or colonizing CF patients chronically.We therefore infer
that the aforementioned genotypes can survive in certain ecolog-
ical niches or industrial products, spread among patients, and
most readily adapt to the lungs of CF patients. This research has
enabled a deeper understanding of the diversity of the B. contami-
nans isolates recovered from CF patients treated in Argentina.
Since a knowledge of currently infectious strains is critical in pre-
scribing patient treatment andmaking prognoses, isolates charac-
terized by the B1 and B8 subtypes have now become the object of
ongoing investigations in our laboratory. This and the forthcom-
ing information will provide deeper insights into the strategies
employed by B. contaminans to adapt and persist within CF pa-
tients.
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